Calumet (CLMT) Q1 2026 Earnings Transcript

Calumet reported Q1 adjusted EBITDA of $50.1 million, down from $55 million, but highlighted a materially stronger setup ahead after completing the Montana Renewables MaxSAF 150 expansion and restarting operations. Specialty Products & Solutions EBITDA was $44.3 million and Performance Brands $12.6 million, while Montana/Renewables EBITDA improved to $10.2 million and SAF volumes are expected to rise 4-5x on an annual run-rate basis. The quarter was pressured by a Shreveport contamination event that caused about 750,000 barrels of lost production and more than $30 million of lost opportunity, though management expects the issue is resolved and liquidity remains supported by improving working capital and debt paydown plans.

Analysis

CLMT is morphing from a “prove it” balance-sheet story into a cash-flow timing trade, but the market will likely key off execution more than headline margin optimism. The important second-order dynamic is that the current commodity spike cuts both ways: it widens spreads, yet it also inflates working capital and amplifies hedge drag precisely when the company wants cleaner deleveraging optics. That means near-term equity performance will be driven as much by how fast inventory/receivables normalize over the next 1-2 quarters as by absolute EBITDA.

The biggest latent winner is the renewable platform’s contract reset, not just the expansion itself. Evergreen SAF offtake with a premium floor becomes much more valuable if policy durability persists and competing biofuel capacity remains slow to restart; that creates an embedded option on future phase-two modular expansion without needing a fresh re-rate today. However, the key risk is that the consensus may be underestimating how fast incremental biodiesel supply can come back if margins stay elevated for several months, which would compress the very spread environment management is implicitly assuming into year-end.

Shreveport is now a confidence test, not a profit center issue: the real question is whether the operational event was idiosyncratic or a signal of brittle process control elsewhere in the chain. If management can show two clean quarters while hedges roll off and working capital unwinds, CLMT has room for a sharp multiple expansion because the equity story shifts from recovery to recurring free cash flow. If not, the stock remains hostage to one-off operational noise and will likely trade as a levered spread proxy rather than a compounder.

Key Decisions for Investors

• Go long CLMT common on a pullback over the next 2-4 weeks, but size as a tactical trade, not a core position; target a 15-25% rerating if Q2 shows working-capital release and clean Shreveport uptime, with downside protected only if operations stay stable.
• Buy CLMT Jan-2027 call spreads to express the deleveraging + SAF monetization option while limiting event risk; best risk/reward if execution validates in the next two quarters and phase-two expansion gets a clear path.
• Pair trade: long CLMT / short a basket of smaller biodiesel names over the next 1-2 quarters; CLMT has a larger integrated feedstock/marketing advantage if renewable capacity remains unevenly restarted, while the shorts are more exposed to margin mean reversion.
• If already long, trim into strength after the next leg of spread-driven rally and re-add only on evidence that margins are converting into cash rather than inventory; watch for a reversal in AR and hedge losses before increasing exposure.
• Set a risk trigger: if biodiesel utilization meaningfully reaccelerates faster than expected into late summer, take profits on CLMT because the market will likely de-rate the “scarcity premium” embedded in the renewables segment.